Invasion of a Recurrent Laryngeal Nerve from Small, Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance.

Background: The success of an active surveillance management approach to low-risk papillary thyroid cancer (PTC) is heavily dependent on proper patient selection. For example, primary tumors located in a subcapsular position immediately adjacent to the trachea or a recurrent laryngeal nerve (RLN) are considered to be inappropriate for active surveillance. Since pre-operative imaging cannot reliably rule out extrathyroidal extension or reveal the full course of the RLN relative to the thyroid gland, it is important for clinicians to understand subcapsular tumor locations and minimum tumor sizes that are most likely to be associated with gross invasion of the RLNs. Methods: We assessed the medical records of 123 patients treated at Memorial Sloan Kettering Cancer Center (MSK) between 1986 and 2015 who had a primary PTC tumor demonstrating gross extrathyroidal extension to either the right or left RLN. Thirty patients with a primary tumor ≤2 cm in diameter demonstrating extrathyroidal extension into an RLN were included in the analysis. Results: Gross invasion of an RLN by tumors ≤2 cm is a rare event that was seen in only 0.8% (35/4,334) of patients with PTC who underwent initial thyroid surgery at MSK between 1986 and 2015. Gross RLN invasion was associated with subcapsular PTC tumors located in either the right paratracheal area (60%), left paratracheal area (36.7%), or right lateral posterior lobe area not adjacent to the trachea (3.3%). Only a quarter of the patients had imaging findings suggestive of extrathyroidal extension and only 30% had clinically apparent vocal paresis/paralysis on pre-operative examination. Invasion of the RLN was not observed for primary tumors <0.9 cm in diameter, regardless of tumor location. Conclusions: Well-differentiated PTC tumors ≥0.9 cm in maximal diameter which are located in the right paratracheal, left paratracheal, and right lateral posterior lobe subcapsular positions are usually not appropriate for active surveillance even in the absence of definitive evidence for nerve invasion on pre-operative imaging or vocal cord examination. Patient selection for active surveillance management should take into account not only the size and growth rate of a tumor but also its location in relation to the expected course of RLNs.

[1]  Tae Yong Kim,et al.  Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea , 2017, The Journal of clinical endocrinology and metabolism.

[2]  Oscar Lin,et al.  Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance , 2017, JAMA otolaryngology-- head & neck surgery.

[3]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[4]  Tae Yong Kim,et al.  Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. , 2018, Thyroid : official journal of the American Thyroid Association.

[5]  A. Miyauchi,et al.  A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. , 2016, Thyroid : official journal of the American Thyroid Association.

[6]  A. Miyauchi Clinical Trials of Active Surveillance of Papillary Microcarcinoma of the Thyroid , 2016, World Journal of Surgery.

[7]  R. Tuttle,et al.  Surgical considerations for papillary thyroid microcarcinomas , 2017, Journal of surgical oncology.

[8]  R. Tuttle,et al.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.

[9]  I. Sugitani,et al.  Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. , 2010, The Journal of clinical endocrinology and metabolism.

[10]  A. Miyauchi,et al.  Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  A. Miyauchi,et al.  Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. , 2014, Thyroid : official journal of the American Thyroid Association.

[12]  P. Vitti,et al.  Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center. , 2020, The Journal of clinical endocrinology and metabolism.

[13]  A. Sanabria,et al.  Active Surveillance in Thyroid Microcarcinoma in a Latin-American Cohort , 2018, JAMA otolaryngology-- head & neck surgery.

[14]  A. Miyauchi,et al.  Revisiting Low-Risk Thyroid Papillary Microcarcinomas Resected Without Observation: Was Immediate Surgery Necessary? , 2016, World Journal of Surgery.

[15]  R. Tuttle,et al.  A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management , 2018, Expert review of endocrinology & metabolism.